Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with Chronic obstructive pulmonary disease

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 6, 2013, Pages 1038-1047

  Karmouty Quintana, Harry ^a   Weng, Tingting ^a   Garcia Morales, Luis J ^b   Chen, Ning Yuan ^a   Pedroza, Mesias ^a   Zhong, Hongyan ^c   Molina, Jose G ^a   Bunge, Raquel ^b   Bruckner, Brian A ^b   Xia, Yang ^a   Johnston, Richard A ^a   Loebe, Matthias ^b   Zeng, Dewan ^c   Seethamraju, Harish ^b   Belardinelli, Luiz ^c   Blackburn, Michael R ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

Adenosine; Extracellular matrix; Hyaluronic acid; Remodeling; Vascular

Indexed keywords

ADENOSINE A2B RECEPTOR; HYALURONIC ACID;

AIRWAY OBSTRUCTION; AIRWAY REMODELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; UPREGULATION;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ADENOSINE DEAMINASE; AGED; ANIMALS; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYALURONIC ACID; HYPERTENSION, PULMONARY; LUNG; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PURINES; PYRAZOLES; RECEPTOR, ADENOSINE A2B; RNA, MESSENGER;

EID: 84890020062     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0089OC     Document Type: Article

References (50)

1. World Health Organization. World health statistics 2008 [accessed Feb. 2013]. Available from: http://www. Who. Int/whosis/whostat/en-whs08-full.pdf.
2. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012;379:1341-1351.
3. Rabinovitch M. Pathobiology of pulmonary hypertension: extracellular matrix. Clin Chest Med 2001;22:433-449.
4. Decramer M, Rennard S, Troosters T, Mapel DW, Giardino N, Mannino D, Wouters E, Sethi S, Cooper CB. COPD as a lung disease with systemic consequences: clinical impact, mechanisms, and potential for early intervention. COPD 2008;5:235-256.
5. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371-1385.
6. Cuttica MJ, Kalhan R, Shlobin OA, Ahmad S, Gladwin M, Machado RF, Barnett SD, Nathan SD. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 2010;104:1877-1882.
7. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 1995;107:1193-1198.
8. Orr R, Smith LJ, Cuttica MJ. Pulmonary hypertension in advanced chronic obstructive pulmonary disease. Curr Opin Pulm Med 2012;18:138-143.
9. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121:2045-2066.
10. Barberà JA, Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs 2009;69:1153-1171.
11. Hoeper MM. Treating pulmonary hypertension in COPD: where do we start? Eur Respir J 2008;32:541-542.
12. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta (1) and bone morphogenetic proteins. Circulation 2001;104:790-795.
13. Kwon YS, Chi SY, Shin HJ, Kim EY, Yoon BK, Ban HJ, Oh IJ, Kim KS, Kim YC, Lim SC. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci 2010;25:1487-1491.
14. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, Maitre B, Housset B, Brandt C, Le Corvoisier P, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009;136:678-687.
15. Aytekin M, Comhair SA, De La Motte C, Bandyopadhyay SK, Farver CF, Hascall VC, Erzurum SC, Dweik RA. High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2008;295:L789-L799.
16. Papakonstantinou E, Kouri FM, Karakiulakis G, Klagas I, Eickelberg O. Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension. Eur Respir J 2008;32:1504-1512.
17. Lennon FE, Singleton PA. Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology. Am J Physiol Lung Cell Mol Physiol 2011;301:L137-L147.
18. Karmouty-Quintana H, Zhong H, Acero L, Weng T, Melicoff E, West JD, Hemnes A, Grenz A, Eltzschig HK, Blackwell TS, et al. The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease. FASEB J 2012;26:2546-2557.
19. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn MR. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 2006;116:2173-2182.
20. Scheibner KA, Boodoo S, Collins S, Black KE, Chan-Li Y, Zarek P, Powell JD, Horton MR. The adenosine A2A receptor inhibits matrixinduced inflammation in a novel fashion. Am J Respir Cell Mol Biol 2009;40:251-259.
21. Collins SL, Black KE, Chan-Li Y, Ahn YH, Cole PA, Powell JD, Horton MR. Hyaluronan fragments promote inflammation by down-regulating the anti-inflammatory A2A receptor. Am J Respir Cell Mol Biol 2011;45:675-683.
22. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011;364:656-665.
23. Zhong H, Belardinelli L, Maa T, Zeng D. Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 2005;32:2-8.
24. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology: XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-552.
25. Zhou Y, Schneider DJ, Morschl E, Song L, Pedroza M, Karmouty-Quintana H, Le T, Sun CX, Blackburn MR. Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury. J Immunol 2011;186:1097-1106.
26. Zhou Y, Schneider DJ, Blackburn MR. Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther 2009;123:105-116.
27. Zhou Y, Murthy JN, Zeng D, Belardinelli L, Blackburn MR. Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS ONE 2010;5:e9224.
28. Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, Taraseviciene-Stewart L, Sung Y, Kraskauskas D, Farkas D, et al. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol 2012;302:L977-L991.
29. West J, Harral J, Lane K, Deng Y, Ickes B, Crona D, Albu S, Stewart D, Fagan K. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol 2008;295:L744-L755.
30. McGovern JP, Sasse SA, Stansbury DW, Causing LA, Light RW. Comparison of oxygen saturation by pulse oximetry and co-oximetry during exercise testing in patients with COPD. Chest 1996;109:1151-1155.
31. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003;200:423-428.
32. Li Y, Jiang D, Liang J, Meltzer EB, Gray A, Miura R, Wogensen L, Yamaguchi Y, Noble PW. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med 2011;208:1459-1471.
33. Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, Westerhof N, Postmus PE, Boonstra A, Vonk-Noordegraaf A. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008;31:759-764.
34. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, Tamm M. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-628.
35. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007;14:1315-1323.
36. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an informationrich system. Eur J Cell Biol 2006;85:699-715.
37. Sertogullarindan B, Gumrukcuoglu HA, Sezgi C, Akil MA. Frequency of pulmonary hypertension in patients with COPD due to biomass smoke and tobacco smoke. Int J Med Sci 2012;9:406-412.
38. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, et al. Global Initiative for Chronic Obstructive Lung Disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
39. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007;131:657-663.
40. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-1665.
41. Weitzenblum E, Chaouat A, Canuet M, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med 2009;30:458-470.
42. Vanoirbeek JA, Rinaldi M, De Vooght V, Haenen S, Bobic S, Gayan-Ramirez G, Hoet PH, Verbeken E, Decramer M, Nemery B, et al. Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. Am J Respir Cell Mol Biol 2010;42:96-104.
43. Ormiston ML, Slaughter GR, Deng Y, Stewart DJ, Courtman DW. The enzymatic degradation of hyaluronan is associated with disease progression in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2010;298:L148-L157.
44. Deudon E, Berrou E, Breton M, Picard J. Growth-related production of proteoglycans and hyaluronic acid in synchronous arterial smooth muscle cells. Int J Biochem 1992;24:465-470.
45. Evanko SP, Angello JC, Wight TN. Formation of hyaluronan- and versicanrich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:1004-1013.
46. West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985;228:1324-1326.
47. Brecht M, Mayer U, Schlosser E, Prehm P. Increased hyaluronate synthesis is required for fibroblast detachment and mitosis. Biochem J 1986;239:445-450.
48. Dentener MA, Vernooy JH, Hendriks S, Wouters EF. Enhanced levels of hyaluronan in lungs of patients with COPD: relationship with lung function and local inflammation. Thorax 2005;60:114-119.
49. Bensadoun ES, Burke AK, Hogg JC, Roberts CR. Proteoglycan deposition in pulmonary fibrosis. Am J Respir Crit Care Med 1996;154:1819-1828.
50. Matthay RA. Favorable cardiovascular effects of theophylline in COPD. Chest 1987;92:22S-26S.